Abbas Hussain - 09 Dec 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ James Dillon, As Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
09 Dec 2025
Transactions value $
-$13,910
Form type
4
Filing time
11 Dec 2025, 16:16:32 UTC
Previous filing
06 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hussain Abbas Director C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE /s/ James Dillon, As Attorney-in-Fact 11 Dec 2025 0001821956

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Sale -$13.9K -504 -24.96% $27.60 1.52K 09 Dec 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.